{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T12:37:00Z","timestamp":1703162220230},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The ectodomain of gp41 is the target of potent binding and neutralizing antibodies (NAbs) and is being explored in new strategies for antibody-based HIV vaccines. Previous studies have suggested that the W164A-3S (3S) and EC26-2A4 (EC26) peptides located in the gp41 ectodomain may be potential HIV vaccine candidates. We assessed 3S- and EC26-specific binding antibody responses and related neutralizing activity in a large panel of chronic HIV-1-infected Portuguese individuals on ART. A similar proportion of participants had antibodies binding to 3S (9.6%) and EC26 (9.9%) peptides but the level of reactivity against 3S was significantly higher compared to EC26, except in the rare patients with double peptide reactivity. The higher antigenicity of 3S was unrelated with disease stage, as assessed by CD4<jats:sup>+<\/jats:sup> T cell counts, but it was directly related with plasma viral load. Most patients that were tested (89.9%, N\u2009=\u2009268) showed tier 1 neutralizing activity, the potency being inversely associated with plasma viral load. In the subset of patients that were tested for neutralization of tier 2 isolates, neutralization breadth was inversely correlated with plasma viral load and directly correlated with CD4<jats:sup>+<\/jats:sup> T cell counts. These results are consistent with a role for neutralizing antibodies in controlling viral replication and preventing the decline of CD4<jats:sup>+<\/jats:sup> T lymphocytes. Importantly, in patients with 3S-specific antibodies, neutralizing titers were inversely correlated with viral RNA levels and proviral DNA levels. Moreover, patients with 3S and\/or EC26-specific antibodies showed a 1.9-fold higher tier 2 neutralization score than patients without antibodies suggesting that 3S and\/or EC26-specific antibodies contribute to neutralization breadth and potency in HIV-1 infected patients. Overall, these results suggest that antibodies targeting the S3 and EC26 epitopes may contribute to reduce viral burden and provide further support for the inclusion of 3S and EC26 epitopes in HIV-1 vaccine candidates.<\/jats:p>","DOI":"10.1038\/s41598-021-88274-9","type":"journal-article","created":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T10:07:24Z","timestamp":1619431644000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Antibody response against selected epitopes in the HIV-1 envelope gp41 ectodomain contributes to reduce viral burden in HIV-1 infected patients"],"prefix":"10.1038","volume":"11","author":[{"given":"Rute","family":"Marcelino","sequence":"first","affiliation":[]},{"given":"Filipa","family":"Gramacho","sequence":"additional","affiliation":[]},{"given":"Francisco","family":"Martin","sequence":"additional","affiliation":[]},{"given":"Pedro","family":"Brogueira","sequence":"additional","affiliation":[]},{"given":"Nuno","family":"Janeiro","sequence":"additional","affiliation":[]},{"given":"Claudia","family":"Afonso","sequence":"additional","affiliation":[]},{"given":"Robert","family":"Badura","sequence":"additional","affiliation":[]},{"given":"Em\u00edlia","family":"Valadas","sequence":"additional","affiliation":[]},{"given":"Kamal","family":"Mansinho","sequence":"additional","affiliation":[]},{"given":"Lu\u00eds","family":"Caldeira","sequence":"additional","affiliation":[]},{"given":"Nuno","family":"Taveira","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 M.","family":"Marcelino","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,4,26]]},"reference":[{"key":"88274_CR1","unstructured":"UNAIDS. Global HIV & AIDS statistics - 2020 fact sheet https:\/\/www.unaids.org\/en\/resources\/fact-sheet. (2020)."},{"key":"88274_CR2","unstructured":"Nations, U. Goal 3: Ensure healthy lives and promote well-being for all at all ages. United Nations 410 Sustainable Development Goals. https:\/\/www.un.org\/sustainabledevelopment\/health\/."},{"key":"88274_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41577-018-0103-6","volume":"19","author":"DR Burton","year":"2019","unstructured":"Burton, D. R. Advancing an HIV vaccine; advancing vaccinology. Nat. Rev. Immunol. 19, 77\u201378. https:\/\/doi.org\/10.1038\/s41577-018-0103-6 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"88274_CR4","doi-asserted-by":"publisher","first-page":"e25506","DOI":"10.1002\/jia2.25506","volume":"23","author":"CW Dieffenbach","year":"2020","unstructured":"Dieffenbach, C. W. & Fauci, A. S. The search for an HIV vaccine, the journey continues. J. Int. AIDS Soc. 23, e25506. https:\/\/doi.org\/10.1002\/jia2.25506 (2020).","journal-title":"J. Int. AIDS Soc."},{"key":"88274_CR5","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1146\/annurev-immunol-080219-023629","volume":"38","author":"KE Stephenson","year":"2020","unstructured":"Stephenson, K. E., Wagh, K., Korber, B. & Barouch, D. H. Vaccines and broadly neutralizing antibodies for HIV-1 prevention. Annu. Rev. Immunol. 38, 673\u2013703. https:\/\/doi.org\/10.1146\/annurev-immunol-080219-023629 (2020).","journal-title":"Annu. Rev. Immunol."},{"key":"88274_CR6","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.immuni.2018.04.029","volume":"48","author":"PD Kwong","year":"2018","unstructured":"Kwong, P. D. & Mascola, J. R. HIV-1 vaccines based on antibody identification, B cell ontogeny, and epitope structure. Immunity 48, 855\u2013871. https:\/\/doi.org\/10.1016\/j.immuni.2018.04.029 (2018).","journal-title":"Immunity"},{"key":"88274_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1084\/jem.20161765","volume":"214","author":"A Escolano","year":"2017","unstructured":"Escolano, A., Dosenovic, P. & Nussenzweig, M. C. Progress toward active or passive HIV-1 vaccination. J Exp Med 214, 3\u201316. https:\/\/doi.org\/10.1084\/jem.20161765 (2017).","journal-title":"J Exp Med"},{"key":"88274_CR8","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz2686","author":"BF Haynes","year":"2019","unstructured":"Haynes, B. F., Burton, D. R. & Mascola, J. R. Multiple roles for HIV broadly neutralizing antibodies. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.aaz2686 (2019).","journal-title":"Sci. Transl. Med."},{"key":"88274_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8020171","author":"R Calado","year":"2020","unstructured":"Calado, R. et al. A prime-boost immunization strategy with vaccinia virus expressing novel gp120 envelope glycoprotein from a CRF02_AG isolate elicits cross-clade tier 2 HIV-1 neutralizing antibodies. Vaccines https:\/\/doi.org\/10.3390\/vaccines8020171 (2020).","journal-title":"Vaccines"},{"key":"88274_CR10","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01839-16","author":"S Xiong","year":"2017","unstructured":"Xiong, S. et al. A helical short-peptide fusion inhibitor with highly potent activity against human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus. J. Virol. https:\/\/doi.org\/10.1128\/jvi.01839-16 (2017).","journal-title":"J. Virol."},{"key":"88274_CR11","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1097\/qad.0b013e32835edc1d","volume":"27","author":"P Borrego","year":"2013","unstructured":"Borrego, P. et al. An ancestral HIV-2\/simian immunodeficiency virus peptide with potent HIV-1 and HIV-2 fusion inhibitor activity. AIDS 27, 1081\u20131090. https:\/\/doi.org\/10.1097\/qad.0b013e32835edc1d (2013).","journal-title":"AIDS"},{"key":"88274_CR12","doi-asserted-by":"publisher","first-page":"14039","DOI":"10.1128\/jvi.78.24.14039-14042.2004","volume":"78","author":"S Mehandru","year":"2004","unstructured":"Mehandru, S. et al. Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10. J. Virol. 78, 14039\u201314042. https:\/\/doi.org\/10.1128\/jvi.78.24.14039-14042.2004 (2004).","journal-title":"J. Virol."},{"key":"88274_CR13","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1007\/s13238-018-0534-7","volume":"9","author":"H Liu","year":"2018","unstructured":"Liu, H., Su, X., Si, L., Lu, L. & Jiang, S. The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects. Protein Cell 9, 596\u2013615. https:\/\/doi.org\/10.1007\/s13238-018-0534-7 (2018).","journal-title":"Protein Cell"},{"key":"88274_CR14","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.immuni.2019.02.008","volume":"50","author":"SJ Krebs","year":"2019","unstructured":"Krebs, S. J. et al. Longitudinal analysis reveals early development of three MPER-directed neutralizing antibody lineages from an HIV-1-infected individual. Immunity 50, 677\u2013691. https:\/\/doi.org\/10.1016\/j.immuni.2019.02.008 (2019).","journal-title":"Immunity"},{"key":"88274_CR15","doi-asserted-by":"publisher","first-page":"29912","DOI":"10.1074\/jbc.m114.569566","volume":"289","author":"RP Lai","year":"2014","unstructured":"Lai, R. P. et al. A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1. J. Biol. Chem. 289, 29912\u201329926. https:\/\/doi.org\/10.1074\/jbc.m114.569566 (2014).","journal-title":"J. Biol. Chem."},{"key":"88274_CR16","doi-asserted-by":"publisher","first-page":"E8892","DOI":"10.1073\/pnas.1807259115","volume":"115","author":"Q Fu","year":"2018","unstructured":"Fu, Q. et al. Structure of the membrane proximal external region of HIV-1 envelope glycoprotein. Proc. Natl. Acad. Sci. U.S.A. 115, E8892\u2013E8899. https:\/\/doi.org\/10.1073\/pnas.1807259115 (2018).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"88274_CR17","doi-asserted-by":"publisher","first-page":"6642","DOI":"10.1128\/jvi.67.11.6642-6647.1993","volume":"67","author":"T Muster","year":"1993","unstructured":"Muster, T. et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67, 6642\u20136647. https:\/\/doi.org\/10.1128\/jvi.67.11.6642-6647.1993 (1993).","journal-title":"J. Virol."},{"key":"88274_CR18","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/eji.201242974","volume":"43","author":"M Zhou","year":"2013","unstructured":"Zhou, M. et al. Identification of a new epitope for HIV-neutralizing antibodies in the gp41 membrane proximal external region by an Env-tailored phage display library. Eur. J. Immunol. 43, 499\u2013509. https:\/\/doi.org\/10.1002\/eji.201242974 (2013).","journal-title":"Eur. J. Immunol."},{"key":"88274_CR19","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1016\/j.vaccine.2012.01.026","volume":"30","author":"M Zhou","year":"2012","unstructured":"Zhou, M. et al. Prime boost vaccination approaches with different conjugates of a new HIV-1 gp41 epitope encompassing the membrane proximal external region induce neutralizing antibodies in mice. Vaccine 30, 1911\u20131916. https:\/\/doi.org\/10.1016\/j.vaccine.2012.01.026 (2012).","journal-title":"Vaccine"},{"key":"88274_CR20","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1089\/aid.2017.0250","volume":"34","author":"O Ringel","year":"2018","unstructured":"Ringel, O. et al. Optimization of the EC26-2A4 epitope in the gp41 membrane proximal external region targeted by neutralizing antibodies from an elite controller. AIDS Res. Hum. Retroviruses 34, 365\u2013374. https:\/\/doi.org\/10.1089\/aid.2017.0250 (2018).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"88274_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/v10040197","author":"O Ringel","year":"2018","unstructured":"Ringel, O. et al. The hard way towards an antibody-based HIV-1 Env vaccine: lessons from other viruses. Viruses https:\/\/doi.org\/10.3390\/v10040197 (2018).","journal-title":"Viruses"},{"key":"88274_CR22","doi-asserted-by":"publisher","first-page":"10981","DOI":"10.1073\/pnas.0504315102","volume":"102","author":"V Vieillard","year":"2005","unstructured":"Vieillard, V., Strominger, J. L. & Debre, P. NK cytotoxicity against CD4+ T cells during HIV-1 infection: a gp41 peptide induces the expression of an NKp44 ligand. Proc. Natl. Acad. Sci. U. S. A. 102, 10981\u201310986. https:\/\/doi.org\/10.1073\/pnas.0504315102 (2005).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"88274_CR23","doi-asserted-by":"publisher","unstructured":"Vieillard, V., Costagliola, D., Simon, A., Debre, P. & French Asymptomatiques a Long Terme Study, G. Specific adaptive humoral response against a gp41 motif inhibits CD4 T-cell sensitivity to NK lysis during HIV-1 infection. AIDS 20, 1795\u20131804, https:\/\/doi.org\/10.1097\/01.aids.0000244198.65263.17 (2006).","DOI":"10.1097\/01.aids.0000244198.65263.17"},{"key":"88274_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41541-019-0117-5","volume":"4","author":"V Vieillard","year":"2019","unstructured":"Vieillard, V. et al. HIV therapeutic vaccine enhances non-exhausted CD4(+) T cells in a randomised phase 2 trial. NPJ Vaccines 4, 25. https:\/\/doi.org\/10.1038\/s41541-019-0117-5 (2019).","journal-title":"NPJ Vaccines"},{"key":"88274_CR25","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1093\/cid\/cit335","volume":"57","author":"C Petitdemange","year":"2013","unstructured":"Petitdemange, C. et al. A single amino-acid change in a highly conserved motif of gp41 elicits HIV-1 neutralization and protects against CD4 depletion. Clin. Infect. Dis. 57, 745\u2013755. https:\/\/doi.org\/10.1093\/cid\/cit335 (2013).","journal-title":"Clin. Infect. Dis."},{"key":"88274_CR26","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ebiom.2017.07.007","volume":"22","author":"O Lucar","year":"2017","unstructured":"Lucar, O. et al. Neutralizing antibodies against a specific human immunodeficiency virus gp41 epitope are associated with long-term non-progressor status. EBioMedicine 22, 122\u2013132. https:\/\/doi.org\/10.1016\/j.ebiom.2017.07.007 (2017).","journal-title":"EBioMedicine"},{"key":"88274_CR27","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3390\/vaccines7030105","volume":"7","author":"B Combadiere","year":"2019","unstructured":"Combadiere, B., Beaujean, M., Chaudesaigues, C. & Vieillard, V. Peptide-based vaccination for antibody responses against HIV. Vaccines Basel 7, 105. https:\/\/doi.org\/10.3390\/vaccines7030105 (2019).","journal-title":"Vaccines Basel"},{"key":"88274_CR28","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.chom.2018.12.001","volume":"26","author":"CA Bricault","year":"2019","unstructured":"Bricault, C. A. et al. HIV-1 neutralizing antibody signatures and application to epitope-targeted vaccine design. Cell Host Microbe 26, 296. https:\/\/doi.org\/10.1016\/j.chom.2018.12.001 (2019).","journal-title":"Cell Host Microbe"},{"key":"88274_CR29","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1038\/nm.4187","volume":"22","author":"P Rusert","year":"2016","unstructured":"Rusert, P. et al. Determinants of HIV-1 broadly neutralizing antibody induction. Nat. Med. 22, 1260\u20131267. https:\/\/doi.org\/10.1038\/nm.4187 (2016).","journal-title":"Nat. Med."},{"key":"88274_CR30","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1128\/jvi.61.8.2639-2641.1987","volume":"61","author":"JW Gnann Jr","year":"1987","unstructured":"Gnann, J. W. Jr., Nelson, J. A. & Oldstone, M. B. Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus. J. Virol. 61, 2639\u20132641. https:\/\/doi.org\/10.1128\/jvi.61.8.2639-2641.1987 (1987).","journal-title":"J. Virol."},{"key":"88274_CR31","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/qai.0b013e318264b307","volume":"61","author":"V Vieillard","year":"2012","unstructured":"Vieillard, V. et al. Specific anti-gp41 antibodies predict HIV-1 disease progression. J. Acquir. Immune Defic. Syndr. 61, 403\u2013405. https:\/\/doi.org\/10.1097\/qai.0b013e318264b307 (2012).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"88274_CR32","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/qad.0b013e3282f35551","volume":"22","author":"V Vieillard","year":"2008","unstructured":"Vieillard, V. et al. CCR5 or CXCR4 use influences the relationship between CD4 cell depletion, NKp44L expression and NK cytotoxicity in SHIV-infected macaques. AIDS 22, 185\u2013192. https:\/\/doi.org\/10.1097\/qad.0b013e3282f35551 (2008).","journal-title":"AIDS"},{"key":"88274_CR33","doi-asserted-by":"publisher","first-page":"6883","DOI":"10.1016\/j.vaccine.2012.09.004","volume":"30","author":"V Vieillard","year":"2012","unstructured":"Vieillard, V., Dereuddre-Bosquet, N., Mangeot-Mederle, I., Le Grand, R. & Debre, P. An HIV gp41 vaccine protects CD4 central memory T cells in SHIV-infected macaques. Vaccine 30, 6883\u20136891. https:\/\/doi.org\/10.1016\/j.vaccine.2012.09.004 (2012).","journal-title":"Vaccine"},{"key":"88274_CR34","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1128\/jvi.71.4.2674-2684.1997","volume":"71","author":"PL Earl","year":"1997","unstructured":"Earl, P. L., Broder, C. C., Doms, R. W. & Moss, B. Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein. J. Virol. 71, 2674\u20132684. https:\/\/doi.org\/10.1128\/jvi.71.4.2674-2684.1997 (1997).","journal-title":"J. Virol."},{"key":"88274_CR35","doi-asserted-by":"publisher","first-page":"e24130","DOI":"10.1371\/journal.pone.0024130","volume":"6","author":"I Bartolo","year":"2011","unstructured":"Bartolo, I. et al. Origin and epidemiological history of HIV-1 CRF14_BG. PLoS ONE 6, e24130. https:\/\/doi.org\/10.1371\/journal.pone.0024130 (2011).","journal-title":"PLoS ONE"},{"key":"88274_CR36","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1089\/aid.2012.0025","volume":"29","author":"FB Freitas","year":"2013","unstructured":"Freitas, F. B., Esteves, A., Piedade, J. & Parreira, R. Novel multiregion hybridization assay for the identification of the most prevalent genetic forms of the human immunodeficiency virus type 1 circulating in Portugal. AIDS Res. Hum. Retroviruses 29, 318\u2013328. https:\/\/doi.org\/10.1089\/aid.2012.0025 (2013).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"88274_CR37","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/jmv.20408","volume":"77","author":"R Parreira","year":"2005","unstructured":"Parreira, R. et al. Genetic analysis of human immunodeficiency virus type 1 nef in Portugal: subtyping, identification of mosaic genes, and amino acid sequence variability. J Med Virol 77, 8\u201316. https:\/\/doi.org\/10.1002\/jmv.20408 (2005).","journal-title":"J Med Virol"},{"key":"88274_CR38","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1089\/088922203766774568","volume":"19","author":"A Esteves","year":"2003","unstructured":"Esteves, A. et al. Spreading of HIV-1 subtype G and envB\/gagG recombinant strains among injecting drug users in Lisbon, Portugal. AIDS Res. Hum. Retroviruses 19, 511\u2013517. https:\/\/doi.org\/10.1089\/088922203766774568 (2003).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"88274_CR39","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1089\/088922202753519089","volume":"18","author":"A Esteves","year":"2002","unstructured":"Esteves, A. et al. Molecular epidemiology of HIV type 1 infection in Portugal: high prevalence of non-B subtypes. AIDS Res. Hum. Retroviruses 18, 313\u2013325. https:\/\/doi.org\/10.1089\/088922202753519089 (2002).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"88274_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/v12030268","author":"V Pimentel","year":"2020","unstructured":"Pimentel, V. et al. Molecular epidemiology of HIV-1 infected migrants followed up in Portugal: trends between 2001\u20132017. Viruses https:\/\/doi.org\/10.3390\/v12030268 (2020).","journal-title":"Viruses"},{"key":"88274_CR41","doi-asserted-by":"publisher","first-page":"7223","DOI":"10.1038\/s41598-019-43420-2","volume":"9","author":"PMM Araujo","year":"2019","unstructured":"Araujo, P. M. M., Carvalho, A., Pingarilho, M., Abecasis, A. B. & Osorio, N. S. Characterization of a large cluster of HIV-1 A1 infections detected in Portugal and connected to several Western European countries. Sci. Rep. 9, 7223. https:\/\/doi.org\/10.1038\/s41598-019-43420-2 (2019).","journal-title":"Sci. Rep."},{"key":"88274_CR42","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1089\/aid.2010.0312","volume":"27","author":"AB Abecasis","year":"2011","unstructured":"Abecasis, A. B. et al. Molecular epidemiological analysis of paired pol\/env sequences from Portuguese HIV type 1 patients. AIDS Res. Hum. Retroviruses 27, 803\u2013805. https:\/\/doi.org\/10.1089\/aid.2010.0312 (2011).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"88274_CR43","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.meegid.2009.06.019","volume":"10","author":"AC Palma","year":"2010","unstructured":"Palma, A. C. et al. Effect of human immunodeficiency virus type 1 protease inhibitor therapy and subtype on development of resistance in subtypes B and G. Infect. Genet. Evol. 10, 373\u2013379. https:\/\/doi.org\/10.1016\/j.meegid.2009.06.019 (2010).","journal-title":"Infect. Genet. Evol."},{"key":"88274_CR44","doi-asserted-by":"publisher","first-page":"5972","DOI":"10.1073\/pnas.0912381107","volume":"107","author":"X Shen","year":"2010","unstructured":"Shen, X. et al. Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution. Proc. Natl. Acad. Sci. U.S.A. 107, 5972\u20135977. https:\/\/doi.org\/10.1073\/pnas.0912381107 (2010).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"88274_CR45","doi-asserted-by":"publisher","first-page":"8925","DOI":"10.1128\/jvi.00758-09","volume":"83","author":"ES Gray","year":"2009","unstructured":"Gray, E. S. et al. Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J. Virol. 83, 8925\u20138937. https:\/\/doi.org\/10.1128\/jvi.00758-09 (2009).","journal-title":"J. Virol."},{"key":"88274_CR46","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1371\/journal.pmed.0030255","volume":"3","author":"ES Gray","year":"2006","unstructured":"Gray, E. S., Meyers, T., Gray, G., Montefiori, D. C. & Morris, L. Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. PLoS Med. 3, e255. https:\/\/doi.org\/10.1371\/journal.pmed.0030255 (2006).","journal-title":"PLoS Med."},{"key":"88274_CR47","doi-asserted-by":"publisher","first-page":"13232","DOI":"10.1128\/jvi.78.23.13232-13252.2004","volume":"78","author":"JM Binley","year":"2004","unstructured":"Binley, J. M. et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78, 13232\u201313252. https:\/\/doi.org\/10.1128\/jvi.78.23.13232-13252.2004 (2004).","journal-title":"J. Virol."},{"key":"88274_CR48","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1742-4690-11-44","volume":"11","author":"LM Molinos-Albert","year":"2014","unstructured":"Molinos-Albert, L. M. et al. Anti-MPER antibodies with heterogeneous neutralization capacity are detectable in most untreated HIV-1 infected individuals. Retrovirology 11, 44. https:\/\/doi.org\/10.1186\/1742-4690-11-44 (2014).","journal-title":"Retrovirology"},{"key":"88274_CR49","doi-asserted-by":"publisher","first-page":"5032","DOI":"10.1128\/jvi.00154-10","volume":"84","author":"J Pietzsch","year":"2010","unstructured":"Pietzsch, J. et al. Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity. J. Virol. 84, 5032\u20135042. https:\/\/doi.org\/10.1128\/jvi.00154-10 (2010).","journal-title":"J. Virol."},{"key":"88274_CR50","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1128\/jvi.00927-07","volume":"82","author":"SM Alam","year":"2008","unstructured":"Alam, S. M. et al. Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection. J. Virol. 82, 115\u2013125. https:\/\/doi.org\/10.1128\/jvi.00927-07 (2008).","journal-title":"J. Virol."},{"key":"88274_CR51","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.3389\/fimmu.2017.01154","volume":"8","author":"LM Molinos-Albert","year":"2017","unstructured":"Molinos-Albert, L. M., Clotet, B., Blanco, J. & Carrillo, J. Immunologic insights on the membrane proximal external region: a major human immunodeficiency virus type-1 vaccine target. Front. Immunol. 8, 1154. https:\/\/doi.org\/10.3389\/fimmu.2017.01154 (2017).","journal-title":"Front. Immunol."},{"key":"88274_CR52","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1093\/cid\/cit335","volume":"57","author":"C Petitdemange","year":"2013","unstructured":"Petitdemange, C. et al. A single amino-acid change in a highly conserved motif of gp41 elicits HIV-1 neutralization and protects against CD4 depletion. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 57, 745\u2013755. https:\/\/doi.org\/10.1093\/cid\/cit335 (2013).","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"88274_CR53","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1084\/jem.20180246","volume":"215","author":"C Kadelka","year":"2018","unstructured":"Kadelka, C. et al. Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity. J. Exp. Med. 215, 1589\u20131608. https:\/\/doi.org\/10.1084\/jem.20180246 (2018).","journal-title":"J. Exp. Med."},{"key":"88274_CR54","doi-asserted-by":"publisher","first-page":"e1005369","DOI":"10.1371\/journal.ppat.1005369","volume":"12","author":"E Landais","year":"2016","unstructured":"Landais, E. et al. Broadly neutralizing antibody responses in a large longitudinal sub-saharan HIV primary infection cohort. PLoS Pathog. 12, e1005369. https:\/\/doi.org\/10.1371\/journal.ppat.1005369 (2016).","journal-title":"PLoS Pathog."},{"key":"88274_CR55","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12977-018-0443-0","volume":"15","author":"E Landais","year":"2018","unstructured":"Landais, E. & Moore, P. L. Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers. Retrovirology 15, 61. https:\/\/doi.org\/10.1186\/s12977-018-0443-0 (2018).","journal-title":"Retrovirology"},{"key":"88274_CR56","doi-asserted-by":"publisher","first-page":"12623","DOI":"10.1128\/jvi.01705-14","volume":"88","author":"P Hraber","year":"2014","unstructured":"Hraber, P. et al. Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies. J. Virol. 88, 12623\u201312643. https:\/\/doi.org\/10.1128\/jvi.01705-14 (2014).","journal-title":"J. Virol."},{"key":"88274_CR57","doi-asserted-by":"publisher","first-page":"5264","DOI":"10.1128\/jvi.00129-15","volume":"89","author":"RA Jacob","year":"2015","unstructured":"Jacob, R. A. et al. Anti-V3\/Glycan and anti-MPER neutralizing antibodies, but not anti-V2\/glycan site antibodies, are strongly associated with greater anti-HIV-1 neutralization breadth and potency. J. Virol. 89, 5264\u20135275. https:\/\/doi.org\/10.1128\/jvi.00129-15 (2015).","journal-title":"J. Virol."},{"key":"88274_CR58","doi-asserted-by":"publisher","first-page":"e30963","DOI":"10.1371\/journal.pone.0030963","volume":"7","author":"DA Ozaki","year":"2012","unstructured":"Ozaki, D. A. et al. International technology transfer of a GCLP-compliant HIV-1 neutralizing antibody assay for human clinical trials. PLoS ONE 7, e30963. https:\/\/doi.org\/10.1371\/journal.pone.0030963 (2012).","journal-title":"PLoS ONE"},{"key":"88274_CR59","first-page":"293","volume":"33","author":"A De Rossi","year":"2010","unstructured":"De Rossi, A. et al. Quantitative HIV-1 proviral DNA detection: a multicentre analysis. New Microbiol. 33, 293\u2013302 (2010).","journal-title":"New Microbiol."},{"key":"88274_CR60","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/978-1-59745-170-3_26","volume":"485","author":"DC Montefiori","year":"2009","unstructured":"Montefiori, D. C. Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol. Biol. 485, 395\u2013405. https:\/\/doi.org\/10.1007\/978-1-59745-170-3_26 (2009).","journal-title":"Methods Mol. Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88274-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88274-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88274-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T07:24:44Z","timestamp":1670052284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88274-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,26]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["88274"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-88274-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,26]]},"assertion":[{"value":"28 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8993"}}